Appointments

Pharmaceutical company announces new management selections

Published in Pain and Central Nervous System Week, November 18th, 2002

Adolor Corporation (NASDAQ:ADLR) announced the appointment of a vice president and several senior directors. These appointments include positions in the clinical, regulatory, and marketing departments.

Adolor discovers, develops, and plans to commercialize proprietary pharmaceutical products for the treatment of pain and to mitigate certain of the side effects that are caused by current pain treatments. The company's lead product candidate, alvimopan, formerly known as ADL 8-2698, is being tested in phase III clinical studies for the management of opioid-induced bowel dysfunction and postoperative ileus. Adolor also has several novel proprietary compounds in...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Pain and Central Nervous System Week

Source: Pain and Central Nervous System Week (2002-11-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry